financetom
Business
financetom
/
Business
/
Take-Two Affirms Full-Year Bookings Outlook; Fiscal First-Quarter Loss Widens
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Take-Two Affirms Full-Year Bookings Outlook; Fiscal First-Quarter Loss Widens
Aug 9, 2024 4:07 AM

06:53 AM EDT, 08/09/2024 (MT Newswires) -- Take-Two Interactive Software ( TTWO ) reported a wider-than-expected loss for the fiscal first quarter while the video game publisher maintained its full-year bookings outlook as it expects the key metric to grow sequentially in the ongoing three-month period.

Net bookings, which are products and services sold digitally and physically, are projected to come in between $1.42 billion and $1.47 billion for the three-month period ending September 30, the company said late Thursday. During the June quarter, net bookings ticked up 1% to $1.22 billion with NBA 2K24, Grand Theft Auto Online and Grand Theft Auto V among the largest contributors.

For fiscal 2025, Take-Two continues to expect net bookings to be in a range of $5.55 billion to $5.65 billion.

Shares of the company rose 2.3% in recent premarket activity Friday.

"We project recurrent consumer spending to increase by approximately 5%, which assumes a low double-digit increase from mobile driven by the addition of Match Factory! and growth in Toon Blast which are partially offset by declines in our hypercasual mobile portfolio and Empires & Puzzles," Chief Financial Officer Lainie Goldstein said during a conference call, according to a Capital IQ transcript.

Net loss for the full year is now expected to be in a range of $3.95 to $4.33 per share versus the prior outlook of $3.50 to $3.90. The consensus on Capital IQ is for a GAAP loss of $3.24 a share. The company kept its full-year revenue guidance of $5.57 billion to $5.67 billion.

Take-Two's loss in the fiscal first quarter widened to $1.52 per share from $1.22 the year before, compared with the Street's view for a $1.37 per-share loss. Revenue increased 4% year over year to $1.34 billion. "Cost of revenue declined 6% to $567 million and operating expenses increased by 8% to $956 million," Goldstein said on the call.

For the current quarter, the company anticipates a net loss of $2.15 to $2.30 and revenue between $1.29 billion and $1.34 billion.

"As we pursue our strategic priorities, we expect to achieve sequential increases in net bookings in fiscal 2026 and 2027, which we believe will drive long-term shareholder value," Chief Executive Strauss Zelnick said in a statement.

Price: 146.48, Change: +7.70, Percent Change: +5.55

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
Jun 18, 2024
11:40 AM EDT, 06/18/2024 (MT Newswires) -- Immunocore Holdings ( IMCR ) said Tuesday it has randomized the first patient in a phase 3 clinical trial of brenetafusp in combination with nivolumab to treat first-line advanced or metastatic cutaneous melanoma, a type of skin cancer. The trial will randomize patients with first-line advanced or metastatic cutaneous melanoma to brenetafusp plus...
What's Going On With Greenwave Technology
What's Going On With Greenwave Technology
Jun 18, 2024
Greenwave Technology Solutions, Inc. ( GWAV ) shares are trading higher Tuesday after the company announced the completion of its recapitalization. The Details: Greenwave said it has strengthened its balance sheet by approximately $80.5 million since February and has a current cash balance of over $26 million, its strongest cash position in company history.  The company also said it is...
Lexaria Bioscience Hires Contract Research Organization For 12-week Study
Lexaria Bioscience Hires Contract Research Organization For 12-week Study
Jun 18, 2024
11:40 AM EDT, 06/18/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Tuesday that it hired a contract research organization to manage its 12-week chronic study, GLP-1-H24-4, to evaluate different DehydraTECH-GLP-1 formulations and other treatments, focusing on goals such as weight loss and reducing blood sugar levels. Preparations for the study with the CRO have started under an initial...
What's Going On With Mustang Bio Stock Tuesday?
What's Going On With Mustang Bio Stock Tuesday?
Jun 18, 2024
Mustang Bio, Inc. ( MBIO ) shares appear to be trending upward Tuesday on continued momentum after the company on Monday announced safety and efficacy data from its Phase 1/2 clinical trial of MB-106, a possible treatment for certain types of blood cancer. 90% of patients treated with MB-106 responded to the treatment with three complete responses. Out of the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved